A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.
Advanced Cancer
DRUG: ENMD-2076
Safety and tolerability of ENMD-2076, Throughout study treatment
Plasma PK, Throughout study treatment|Evidence of benefit (tumor response, clinical benefit, or tumor marker improvement, if appropriate), Throughout study treatment
A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.